Insider Selling: Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $1,181,630.76 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 37,524 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $31.49, for a total value of $1,181,630.76. Following the completion of the transaction, the insider directly owned 25,249 shares in the company, valued at $795,091.01. This trade represents a 59.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Krempa also recently made the following trade(s):

• On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $33.39, for a total value of $1,428,991.83.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.47, for a total value of $619,298.13.

Eton Pharmaceuticals Stock Down 4.4%

NASDAQ:ETON opened at $30.45 on Friday. The company has a market capitalization of $834.09 million, a price-to-earnings ratio of -434.94 and a beta of 0.82. Eton Pharmaceuticals, Inc. has a one year low of $13.09 and a one year high of $35.66. The stock has a 50-day simple moving average of $27.08 and a 200 day simple moving average of $20.21. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The company had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. Sell-side analysts predict that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Quarry LP acquired a new position in shares of Eton Pharmaceuticals during the third quarter valued at about $37,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at about $44,000. Legal & General Group Plc acquired a new position in shares of Eton Pharmaceuticals during the second quarter valued at about $41,000. China Universal Asset Management Co. Ltd. acquired a new position in Eton Pharmaceuticals in the fourth quarter worth about $74,000. Finally, SG Americas Securities LLC acquired a new position in Eton Pharmaceuticals in the fourth quarter worth about $109,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ETON shares. HC Wainwright upped their price target on Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a report on Friday, May 15th. Wall Street Zen raised shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Zacks Research cut shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. Finally, B. Riley Financial upped their price target on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a report on Friday, March 20th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eton Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $41.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.